Organizational and Management Impact Analysis of Using the New Subcutaneous Formulation of Tocilizumab in Selected Italian Rheumatology Centers

Nov 1, 2014, 00:00 AM
10.1016/j.jval.2014.08.2632
https://www.valueinhealthjournal.com/article/S1098-3015(14)04581-1/fulltext
Section Title : Disease-Specific Studies
Section Order : 332
First Page : A383
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04581-1&doi=10.1016/j.jval.2014.08.2632
HEOR Topics :
Tags :
Regions :